Citigroup
ABVC icon

Citigroup’s ABVC BioPharma ABVC Stock Holding History

Citigroup’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$853 Buy
+540
New +$673 ﹤0.01% 5421

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's ABVC Position: Q2 2026 in Review

Citigroup opened a new position in ABVC BioPharma (ABVC) in Q2 2026: 540 shares worth $853. The stake represents ﹤0.01% of the portfolio and ranks #5421 among its holdings.

15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Citigroup held 540 shares of ABVC BioPharma worth $853 as of Q2 2026.
  • ABVC BioPharma was a new Citigroup position in Q2 2026.
  • ABVC BioPharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5421 holding.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.